CytomX Therapeutics, Inc. (CTMX) News
Follow CytomX Therapeutics, Inc. (CTMX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
CTMX: Lead ADC demonstrates promising efficacy in late-line CRC, with broad pipeline and strong financial runway
Masked biologics technology enables targeting of challenging cancer antigens, with lead ADC showing strong efficacy and improved tolerability in late-line CRC. Dose optimization and combination studies are advancing, wit
NEWS | Sep 14, 2026, 07:19 PM UTC
L
CTMX: Lead ADC shows promising efficacy and safety in late-line CRC, with broad expansion plans
Masked biologics technology enables targeting of challenging cancer antigens, with lead ADC showing strong efficacy and manageable GI toxicity in late-line CRC. Dose optimization and registrational plans are underway, wi
NEWS | Sep 14, 2026, 06:52 PM UTC
M
CTMX lead EpCAM ADC shows robust efficacy in late-line CRC
CTMX’s lead EpCAM-targeting ADC reported robust efficacy in late-line colorectal cancer at a conference, alongside manageable safety and a clear regulatory path. The company also highlighted expansion into combinations a
EQUITY | Sep 09, 2026, 04:15 PM UTC
L
CTMX Varseta-M reports robust late-line CRC efficacy
TradingView reports a conference highlighted strong clinical progress for Varseta-M in late-line colorectal cancer, with promising efficacy and safety, plus a pivotal study planned for next year.
EQUITY | Sep 09, 2026, 03:17 PM UTC
L
CTMX drug candidates Varseta-M and CX-801 show clinical progress
CTMX says Varseta-M, an EpCAM-targeting ADC, is advancing in late-line colorectal cancer with FDA Fast Track status, alongside combination and expansion studies. CX-801 is also progressing in late-line settings, with dat
REGULATION | Sep 08, 2026, 07:35 PM UTC
M
CTMX Varseta-M and CX-801 progress in phase I oncology trials
Varseta-M, an EpCAM-targeting ADC, is advancing in phase I for late-line colorectal cancer with Fast Track status and plans for pivotal studies and expansion. CX-801, a masked interferon alfa-2b, is progressing in phase
EQUITY | Sep 08, 2026, 07:05 PM UTC
L
CytomX management set for September investor conference appearances
CytomX Therapeutics said management will participate in investor conferences scheduled for September.
EQUITY | Sep 01, 2026, 12:07 PM UTC
L
CTMX - CytomX Therapeutics to Present at Upcoming September Investor Conferences
CTMX - CytomX Therapeutics to Present at Upcoming September Investor Conferences
EQUITY | Sep 01, 2026, 12:01 PM UTC
L
CytomX wins FDA Fast Track for Varseta-M in metastatic colorectal cancer
CytomX Therapeutics announced FDA Fast Track designation for Varseta-M in relapsed/refractory metastatic colorectal cancer.
REGULATION | Aug 27, 2026, 12:07 PM UTC
L
CytomX Therapeutics gets FDA Fast Track for Varseta-M in mCRC
CytomX Therapeutics says the FDA granted Fast Track designation to Varseta-M for relapsed/refractory metastatic colorectal cancer (R/R mCRC).
REGULATION | Aug 27, 2026, 12:00 PM UTC
L
CytomX Appoints Alejandra Carvajal as Chief Legal Officer
CytomX hires new Chief Legal Officer
EQUITY | Aug 03, 2026, 12:00 PM UTC
L
CTMX - CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
CTMX - CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
EARNINGS | Jul 30, 2026, 12:00 PM UTC
L
Citizens healthcare analysts hold an analyst/industry conference call
Citizens healthcare analysts hold an analyst/industry conference call
EQUITY | Jul 13, 2026, 08:56 AM UTC